AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 11/07/23

2023-11-07 15:19:08 ET Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Conference Call November 07, 2023 08:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief Executive Officer Chintu Patel - Co-Fou...

2023-11-07 12:53:17 ET More on AbbVie, GSK, etc. Arexvy Puts GSK Back On The Growth Prescription (Rating Upgrade) GSK plc (GSK) Q3 2023 Earnings Call Transcript GSK plc 2023 Q3 - Results - Earnings Call Presentation J&J’s patent win against Viatris...

2023-11-07 06:04:37 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal Pharmaceuticals raises its FY outlook Amneal to reorganize and simplify corporate structure Seeking Alpha’s Quant Rating on Amn...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Affirmed Pr...

Amneal Pharmaceuticals Inc. Class A (AMRX) is expected to report $0.1 for Q3 2023

2023-11-06 11:32:09 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is $0.13 (-7.1% Y/Y) and the consensus Revenue Estimate is $604.53M (+10.8% Y/Y). Over the...

2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...

2023-10-23 16:23:28 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal to reorganize and simplify corporate structure Amneal gets approval for generic injectable on FDA's shortage list For further details ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023,...